Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab short-duration infusion in previously untreated advanced follicular lymphoma
jRCT2080224636Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in follicular lymphoma (FL), sponsored by Chugai Pharmaceutical Co., Ltd. Started Apr 2019; status: completed.
02
Drugs
obinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2080224636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224636.